How Will the Oral Transmucosal Drugs Market Grow? Key Trends and Opportunities for 2025 and Beyond
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the oral transmucosal drugs market grown in recent years?
There has been robust growth in the oral transmucosal drugs market in recent times. The market is anticipated to expand from $39.7 billion in 2024 to $43.53 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.6%. The growth witnessed in the historic period is a consequence of several factors like progressive diagnostic capabilities, elder demographic, pollution in the environment, genetic predispositions, improved detection rates, rapid alleviation through speedy drug absorption, and superior compliance.
How is the oral transmucosal drugs market size expected to evolve during the forecast period?
Anticipated to witness robust growth in the coming years, the size of the oral transmucosal drugs market is projected to expand to $62.03 billion by 2029, with a compound annual growth rate (CAGR) of 9.3%. This growth during the predicted period can be linked to progress in personalized medicine, escalated research on innovative drug delivery systems, an increasing elderly population, heightened understanding of oral health, the surging demand for non-invasive medical procedures, and changing regulatory environments. Key trends observed during this period include the embrace of innovative formulations, personalized medicinal practices, advancements in telehealth, the amalgamation of digital health technology and modern updates in the pharmaceutical sector.
Get your oral transmucosal drugs market report here!
https://www.thebusinessresearchcompany.com/report/oral-transmucosal-drugs-global-market-report
Which key drivers are propelling the oral transmucosal drugs market’s growth?
The escalating occurrence of Parkinson’s disease is anticipated to drive the expansion of the oral transmucosal drug market in the future. Parkinson’s disease is a progressive neurological disorder that causes tremors, rigidity, and mobility issues due to a decrease in dopamine-producing cells in the brain. Increased aging demographics, exposure to environmental pollutants, genetic predispositions, and improvements in diagnostic technologies resulting in higher detection rates are all contributing factors to the growing prevalence of Parkinson’s disease. Oral transmucosal medications contribute significantly to the treatment of Parkinson’s disease by enabling quick drug absorption and tackling digestive obstacles, which results in quicker relief, improved treatment adherence, and potentially reduced motor complications. As of December 2022, the Parkinson’s Foundation, a US-based charity, reports that nearly 1 million people in the United States are currently diagnosed with Parkinson’s disease (PD). This figure is projected to rise to 1.2 million by 2030. Consequently, the escalating prevalence of Parkinson’s disease is spurring the growth of the oral transmucosal drug market.
What are the market segments in the oral transmucosal drugs industry?
The oral transmucosal drugs market covered in this report is segmented –
1) By Product Type: Tablets, Films, Liquid And Spray, Other Product Types
2) By Indication: Opioid Dependence, Nausea And Vomiting, Erectile Dysfunction, Neurological Disorders, Other Indications
3) By Route Of Administration: Sublingual Mucosa, Buccal Mucosa, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Tablets: Buccal Tablets, Sublingual Tablets, Effervescent Tablets
2) By Films: Buccal Films, Sublingual Films, Mucoadhesive Films
3) By Liquid And Spray: Sublingual Liquid Solutions, Oral Sprays (Pain Relief, Sleep Aids), Mucosal Gels
4) By Other Product Types: Lozenges, Pastilles, Chewing Gums
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15627&type=smp
Which leading companies are shaping the growth of the oral transmucosal drugs market?
Major companies operating in the oral transmucosal drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi-Aventis LLC, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly & Company Ltd., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Actavis Pharma Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Endo Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Mallinckrodt Pharmaceuticals Plc, Glenmark Pharmaceuticals Limited, Jubilant Life Sciences Limited, Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Wockhardt Ltd.
Which trends are expected to transform the oral transmucosal drugs market?
Leading enterprises in the oral transmucosal drug market are heavily invested in creating innovative drug delivery mechanisms, such as a sublingual vitamin spray. The goal is to increase the effectiveness of drug delivery, simplify the usage process for patients, and fine-tune therapeutic results. A sublingual vitamin spray offers a unique oral transmucosal drug delivery mechanism, which delivers nutrients directly into the bloodstream through the mucous membranes beneath the tongue. This approach circumvents the gastrointestinal tract and liver metabolism, enabling quick and effective vitamin absorption. For example, in October 2022, Absorvit was launched by Vestige Marketing, a wellness and fitness firm based in India. This sublingual vitamin spray promises fast absorption and instant results. It provides absorption efficiency that is 3-10 times higher than conventional oral methods. It includes improved versions and accurate quantities of essential vitamins such as B12, C, D, and multivitamins, guaranteeing optimum nutrition delivery. Absorvit provides an easy and efficient method to supplement crucial nutrients, thereby promoting overall wellbeing.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15627
Which geographic areas are influencing the growth of the oral transmucosal drugs market?
North America was the largest region in the oral transmucosal drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral transmucosal drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Oral Contraceptive Pills Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oral-contraceptive-pills-global-market-report
Computer-Aided Oral And Maxillofacial Surgery Global Market Report 2024
Oral Cancer Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oral-cancer-treatment-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
